Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP

Recursion Pharmaceuticals, Inc. RXRX

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$74.7M
▲ 26.9% YoY
$-644.8M
$-378.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The company has advanced a portfolio of differentiated internal programs and strategic partnerships powered by its integrated drug discovery and development platform, the Recursion Operating System. This platform provides end-to-end, AI-native capabilities that span from novel biological ideas through the clinic, integrating multimodal biological data generation, AI-powered small molecule synthesis, and AI-enabled clinical development. The company's two heavy-infrastructure sites in Salt Lake City, Utah and Milton Park, Oxfordshire are designed for the massive-scale data generation that drives its platform. In partnership with Roche and Genentech, Recursion built the first whole-genome CRISPR knockout map generated from a subset of 1 trillion internally manufactured iPSC-derived neuronal cells.

Written from the business description in Recursion Pharmaceuticals, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 25 February 2026. Every sentence was checked against that document before publication.

Growth

USD 74.7M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 74.7 · Net income -644.8
30.0M60.0M-250.0M-500.0M
201920222025
Compound annual growth
+23.3%
+79.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +79.9% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−863 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -867.9% · Net -863.4%
-1000%-2000%
201920222025
ROE
FY2025 · ROE -59.5%
-20%-40%-60%
201920222025
Three returns, three denominators.

Each USD of equity lost 60 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -378.3
-150M-300M
201920222025

Total assetsUSD 1.5B
EquityUSD 1.1B
CashUSD 743.3M
Gross debtUSD 9.6M
Net debtUSD -733.7M
Current ratio5.50×

The company holds more cash than debt.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
RXRX, 7-year financial record
Metric 2025202420232022202120202019
Revenue $B0.10.10.00.00.00.00.0
Operating income $B−0.6−0.5−0.4−0.2−0.2−0.1−0.1
EBITDA $B−0.6−0.4−0.3−0.2−0.2−0.1−0.1
Income tax $B−0.0−0.0−0.00.00.00.00.0
Net income $B−0.6−0.5−0.3−0.2−0.2−0.1−0.1
Free cash flow $B−0.4−0.4−0.3−0.1−0.2−0.1−0.1
EPS, diluted $−1.44−1.69−1.58−1.36−1.49−3.99−2.87
Dividend / sh $◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %−59.5−61.9−69.1−46.6———
Shares out B0.530.400.230.190.170.02◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 26 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 13 checks were skipped: cost of revenue is not tagged before 2020. 12 checks were skipped: EPS is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2019

Share this section

Download image